Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI Study of Fedratinib and Fluconazole in Healthy Adults
NCT04702464Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fedratinib in myelofibrosis (MF), sponsored by Celgene Corporation. Primary endpoints: Maximum observed plasma concentration and Area under the plasma concentration-time curve. Started Jan 2021; status: completed.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04702464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702464.